Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
609 studies found for:    Open Studies | "Leukemia, Lymphoid"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Leukemia, Lymphoid" (609 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Unknown  Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
Conditions: Leukemia, Lymphoid;   Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Lenalidomide plus dexamethasone
2 Recruiting Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Conditions: Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
Interventions: Drug: MLN 9708;   Drug: Vincristine;   Drug: Cytarabine;   Drug: Doxorubicin;   Drug: Mercaptopurine;   Drug: Cyclophosphamide;   Drug: Methotrexate
3 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
4 Not yet recruiting Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Recurrent T Lymphoblastic Leukemia/Lymphoma;   Refractory B Lymphoblastic Lymphoma;   Refractory T Lymphoblastic Lymphoma;   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
Interventions: Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
5 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
6 Recruiting Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
7 Recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine Sulfate
8 Recruiting Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Lymphocytic Leukemia
Interventions: Drug: Lirilumab;   Drug: Rituximab
9 Recruiting Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Ph Positive Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia
Interventions: Drug: bortezomib;   Drug: doxorubicin hydrochloride;   Drug: pegaspargase;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate
10 Recruiting Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Conditions: Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
11 Unknown  Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome, Ph^1^, Absent;   B-cell Childhood Acute Lymphoblastic Leukemia
Intervention: Drug: Idarubicin(IDA)
12 Not yet recruiting Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
13 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
14 Recruiting Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Conditions: Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: Laboratory Biomarker Analysis
15 Recruiting Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
16 Not yet recruiting Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)
Conditions: Acute Lymphoblastic Leukaemia;   Chronic Lymphocytic Leukaemia
Intervention: Genetic: UCART19
17 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Mixed Glioma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Glioma;   Lymphoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Colorectal Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Melanoma;   Recurrent Pancreatic Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Other: Pharmacological Study;   Drug: Romidepsin
18 Not yet recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   CD19-Positive Neoplastic Cells Present;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Interventions: Biological: Blinatumomab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Vincristine Sulfate
20 Recruiting Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Conditions: Leukemia;   Acute Lymphocytic Leukemia
Interventions: Drug: Blinatumomab;   Behavioral: Phone Calls

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years